A Phase 3 interventional study of SM-13496 in Bipolar I Disorder, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 8 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I disorder.
The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120 mg/day) in patients with bipolar I disorder.
Sumitomo Pharma Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who completed the D1002001 study
・Patients who completed the D1002001 study and who are considered by the investigator to be eligible and without safety concerns.
Patients who did not participate in the D1002001 study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily orally SM-13496 20-120 mg flexibly dosed
Drug: SM-13496
Also known as: Lurasidone
Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)
The number and percentage of subjects with at least one adverse event and adverse drug reaction
Time frame: 28, 52 weeks
Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score
Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.
Time frame: Baseline, 52 weeks and each month
Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.
YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.
Time frame: Baseline, 52 weeks and each month
Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.
The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.
Time frame: Baseline to 52 weeks
| Milestone | SM-13496 20-120mg |
|---|---|
| Started | 495 |
| Completed | 339 |
| Not completed | 156 |
| Withdrew: Adverse event | 59 |
| Withdrew: Lack of efficacy | 23 |
| Withdrew: Withdrawal by subject | 58 |
| Withdrew: Noncompliance | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Other reason | 7 |
The number and percentage of subjects with at least one adverse event and adverse drug reaction
| Participants | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR) | 352 | 169 |
Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.
| units on a scale | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score | -4.4 ± 12.09 | 1.1 ± 12.58 |
YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.
| units on a scale | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score. | -1.0 ± 4.54 | -2.0 ± 6.73 |
The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.
| Participants | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder. | 14 | 18 |
Collected over Adverse event data was collected for 28 weeks (outside Japan) and 52 weeks (Japan).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SM-13496 20-120mg (Overall, 28 Weeks) | 0/495 (0%) | 19/495 (3.8%) | 250/495 (50.5%) |
| SM-13496 20-120mg (Japan, 52 Weeks) | 0/199 (0%) | 12/199 (6%) | 137/199 (68.8%) |
| Event | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| Disease progressionGeneral disorders | 8/495 | 3/199 |
| Suicide attemptPsychiatric disorders | 3/495 | 1/199 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/495 | 1/199 |
| Blood potassium decreasedInvestigations | 1/495 | 1/199 |
| Glucose urine presentInvestigations | 1/495 | 1/199 |
| Weight decreasedInvestigations | 1/495 | 1/199 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/495 | 1/199 |
| Lactic acidosisMetabolism and nutrition disorders | 0/495 | 1/199 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/495 | 1/199 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/495 | 1/199 |
| Event | SM-13496 20-120mg (Overall, 28 Weeks) | SM-13496 20-120mg (Japan, 52 Weeks) |
|---|---|---|
| AkathisiaNervous system disorders | 91/495 | 60/199 |
| NasopharyngitisInfections and infestations | 51/495 | 53/199 |
| NauseaGastrointestinal disorders | 35/495 | 24/199 |
| SomnolenceNervous system disorders | 41/495 | 24/199 |
| Weight increasedInvestigations | 31/495 | 17/199 |
| HeadacheNervous system disorders | 37/495 | 16/199 |
| ParkinsonismNervous system disorders | 34/495 | 15/199 |
| VomitingGastrointestinal disorders | 17/495 | 13/199 |
| DiarrhoeaGastrointestinal disorders | 14/495 | 10/199 |
| Disease progressionGeneral disorders | 16/495 | 10/199 |
Safety population-received at least one dose of study medication
| Age, Continuous(years) | SM-13496 20-120mg |
|---|---|
| Mean | 42.6 ± 12.78 |
| Sex: Female, Male(Participants) | SM-13496 20-120mg |
|---|---|
| Female | 259 |
| Male | 236 |
| Race (NIH/OMB)(Participants) | SM-13496 20-120mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 225 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 270 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | SM-13496 20-120mg |
|---|---|
| Japan | 199 |
| Philippines | 8 |
| Taiwan | 7 |
| Ukraine | 117 |
| Malaysia | 11 |
| Slovakia | 15 |
| Lithuania | 9 |
| Russia | 129 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2014 to primary completion in Feb 2018, 48 months.
Results were first posted in Jul 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone